|
Analysis of overall survival (OS) based on tumor target lesion change in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC). |
|
|
Honoraria - Astellas Pharma; Medivation; Novartis |
Consulting or Advisory Role - Aveo; Bristol-Myers Squibb; Exelixis; Genentech; Myriad Pharmaceuticals; Novartis; Pfizer |
Research Funding - Medivation |
|
|
Consulting or Advisory Role - Eisai; Exelixis; Novartis; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Honoraria - Alkermes; Altor BioScience; AVEO |
Consulting or Advisory Role - Eisai |
Speakers' Bureau - Exelixis; Pfizer; Prometheus |
Research Funding - Altor BioScience; Amgen; Bayer; Bristol-Myers Squibb; Eisai; Genentech; GlaxoSmithKline; Pfizer |
|
|
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi |
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Pfizer |
|
|
Consulting or Advisory Role - Janssen; Novartis; Roche |
Travel, Accommodations, Expenses - Celgene; Janssen; Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; Pfizer |
Speakers' Bureau - Pfizer |
Travel, Accommodations, Expenses - Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Pfizer (Inst); Roche Canada (Inst) |
Travel, Accommodations, Expenses - Novartis |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen; Novartis; Sanofi |
Research Funding - Bristol-Myers Squibb; Janssen; Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Bayer; CVS Caremark; Johnson & Johnson; Merck; Sotio |
Consulting or Advisory Role - AstraZeneca; Bayer; CVS Caremark; Johnson & Johnson; Merck; Sotio |
Research Funding - Active Biotech (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Johnson & Johnson (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst) |
Other Relationship - American Cancer Society; UpToDate |
|
|
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Eisai; Exelixis; Pfizer |
Speakers' Bureau - Astellas Pharma; Bayer; Celgene; Sanofi |
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Exelixis |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis |
Research Funding - AstraZeneca/MedImmune; Roche/Genentech |
|
|
Honoraria - NCCN; UpToDate |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Pfizer; Prometheus; Roche/Genentech |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst) |